COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Hemab Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)
Close on Oct 19, 2026
- Market cap
- $966.27M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.80 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 21, 2026 | Before market open | – | $-23.98 | – |
Press releases
Announcements Hemab Therapeutics filed with the SEC
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Hemab Therapeutics Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K